1. Home
  2. CULP vs SCYX Comparison

CULP vs SCYX Comparison

Compare CULP & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Culp Inc.

CULP

Culp Inc.

N/A

Current Price

$3.31

Market Cap

43.8M

ML Signal

N/A

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$5.30

Market Cap

51.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CULP
SCYX
Founded
1972
1999
Country
United States
United States
Employees
N/A
29
Industry
Textiles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.8M
51.1M
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
CULP
SCYX
Price
$3.31
$5.30
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
11.7K
246.4K
Earning Date
03-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
47.06
61.36
EPS
N/A
N/A
Revenue
$203,482,000.00
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$8.42
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.70
$0.57
52 Week High
$4.75
$5.62

Technical Indicators

Market Signals
Indicator
CULP
SCYX
Relative Strength Index (RSI) 44.24 63.26
Support Level $3.07 $0.65
Resistance Level $3.50 $5.42
Average True Range (ATR) 0.14 0.46
MACD -0.03 0.01
Stochastic Oscillator 29.04 88.14

Price Performance

Historical Comparison
CULP
SCYX

About CULP Culp Inc.

Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: